09/01/2026
As biologic formulations move toward larger volumes and higher viscosities, delivery challenges are increasingly shaped by system compatibility between primary container and autoinjector platforms.
Our latest blog explores how early alignment and robust testing between autoinjector and primary container platforms can help define a validated design space, supporting diverse formulations while reducing downstream development risk.
💡Explore insights from SHL Medical and Stevanato Group on high-viscosity biologic delivery. https://bit.ly/4jFXJaV